9.43
-1.77%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Yifan Pharmaceutical Co
Its shares trade on Shenzhen under the ticker 002019.SZ. It has been listed since 13 July 2004. In the fiscal year to 31 December 2025, it reported revenue of CN¥5.13bn and net income of CN¥402.0m. At that date it held total assets of CN¥12.85bn and shareholders' equity of CN¥8.83bn.
Yifan Pharmaceutical Co., Ltd. engages in the research, development, production and sale of pharmaceutical products, active pharmaceutical ingredients and polymer materials. The company is headquartered in Hangzhou, Zhejiang. The company went IPO on 2004-07-13. The firm operates in three segments, including Pharmaceuticals, Pharmaceutical Raw Material and Intermediates, as well as Polymer Materials. The firm's main products include D-calcium pantothenate, D- panthenol, poly butylenes succinate and others. The firm distributes its products in domestic and overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 13 Jul 2004
- Employees
- 4,338
- Website
- yifanyy.com ↗
Leadership
Pay as last reported
- Mr. Xianfeng ChengChairman of the Board, President, since 2014CN¥624,000
- Mr. Dawei ZhangChief Financial Officer, Secretary of the ChairmanCN¥240,000
- Mr. Deqi FengVice President, Secretary of the Board, Director, since 2016CN¥480,000
- Mr. Hang LinVice President, Director, since 2012CN¥564,000
- Ms. Yuhong GengVice PresidentCN¥1.9m
- Mr. Ximing LiVice PresidentCN¥2.7m
- Ms. Haixia YuSpecial Assistant to the ChairmanCN¥183,000
- Mr. Yiqun YeDirectorCN¥480,000
- Mr. Benyu ZhouDirectorCN¥480,000
- Mr. Genhong ChengIndependent DirectorCN¥100,000
- Mr. Hongquan LiuIndependent DirectorCN¥100,000
- Ms. Yuhong ZengIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 70
- Environment
- 74
- Social
- 53
- Governance
- 85
- Women in the workforce
- 42.85017%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Yifan Pharmaceutical's 4,338 employees support its three business segments effectively.
- D-calcium pantothenate and D-panthenol are key products in the Pharmaceuticals segment.
- Polymer materials like poly butylenes succinate are produced for diverse applications.
Weaknesses
- Hangzhou headquarters limits international expansion opportunities for Yifan Pharmaceutical.
- The company's focus on domestic markets may hinder overseas growth potential.
- Lack of detailed information on specific overseas market presence is a limitation.
Opportunities
- Expanding polymer materials production could leverage global demand for sustainable products.
- Growing demand for D-calcium pantothenate in health supplements presents new markets.
- Increasing pharmaceutical raw material exports to international markets offers growth.
Threats
- Competition from other CN pharmaceutical companies may impact market share.
- Overreliance on domestic market sales could lead to revenue volatility.
- Regulatory changes in the Health Care sector might affect product approvals.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.